ALERT: Colon Cancer SURGING

Yellow warning sign displaying the word 'CANCER' against a blue sky — COLON CANCER ALERT!

Half of colorectal cancer cases in Americans under 50 are now landing in 45–49-year-olds—yet most people in that eligible age band still aren’t getting screened.

Story Snapshot

A 2026 American Cancer Society update shows colorectal cancer trends have stopped improving overall, while rectal cancer incidence rises about 1% a year.
Deaths from colorectal cancer in adults under 50 have been increasing about 1% annually since the mid-2000s, and most under-50 diagnoses are found at advanced stages.
Even after national guidelines lowered the recommended starting age to 45, screening among 45–49-year-olds remains low—roughly 22.5% in BRFSS 2022 and about 37% in the ACS report.
Hospital systems report surges in screening volume among 45–49-year-olds, but population-level numbers show many Americans still aren’t being reached.

The age-45 screening change happened—uptake still lags

U.S. guidelines moved years ago, but behavior hasn’t followed. The American Cancer Society lowered its recommended starting age for average-risk colorectal cancer screening to 45 in 2018, and the U.S.

Preventive Services Task Force followed in 2021. Yet national survey data show only about 22.5% of adults ages 45–49 reported being up to date on testing in 2022, even as this group faces a growing share of under-50 diagnoses.

Researchers tracking the gap point to practical barriers that conservatives have been warning about for years: coverage churn, confusing healthcare rules, and uneven access outside major metro areas. Data also show screening rates are lower for people with less education or without insurance.

After adjusting for multiple factors, some “social needs” measures did not fully explain the shortfall, which suggests the problem may be more basic—patients not being reached, not being scheduled, or not understanding the urgency.

Rising under-50 cases collide with late detection

The trend line is hard to ignore. Colorectal cancer incidence in adults under 50 has risen for years, with one analysis showing about 2.4% annual increases from 2012 to 2021.

The American Cancer Society’s reporting also highlights rising rectal cancer incidence at about 1% per year. The most sobering metric is stage at diagnosis: roughly three-quarters of colorectal cancers in people under 50 are found at advanced stages, when treatment is harder and outcomes worsen.

That reality is exactly why screening is not “just another medical appointment.” Colonoscopy can remove precancerous polyps before they turn into cancer, and stool-based tests can flag warning signs early.

The ACS emphasizes that about half of colorectal cancer diagnoses in under-50 adults occur in 45–49-year-olds—people who are already within the recommended screening window. When the system misses that window, patients are more likely to enter care only after symptoms appear.

Colorectal cancer is rising in adults under 50, yet too few people in this age group get screened in time to catch it early. https://t.co/Ons3QeatnF

— ABC News (@ABC) March 2, 2026

Hospitals report a surge, but national coverage remains thin

One of the biggest contradictions in the data is the difference between health-system volume and the nation’s overall screening coverage. A Vizient analysis reported that monthly colorectal screening volumes in 45–49-year-olds rose dramatically after guideline changes—far outpacing growth seen in older age bands.

That suggests hospitals and large systems are building capacity and pushing reminders. But the same story’s “hard part” is reaching ordinary Americans outside well-organized systems and keeping them engaged year after year.

Kaiser Permanente research adds an important detail: screening yield in 45–49-year-olds appears comparable to that in slightly older adults, supporting the decision to start at 45. That matters because it grounds the policy shift in real pathology findings rather than politics.

It also means the low participation rate is not a minor administrative issue; it is a missed opportunity for prevention at a time when people are working, raising families, and often juggling high-deductible plans and limited time off.

What needs to change—and what the data can’t yet answer

Experts involved in the research call for better outreach, clear education, and policies that improve access. The open question is which obstacle is dominant: cost concerns, lack of primary care continuity, scheduling friction, embarrassment, misinformation, or uneven insurance coverage for follow-up colonoscopies after positive stool tests.

Several studies note data limitations, including self-reported screening in surveys and missing information such as family history, which can complicate risk assessment and messaging.

The takeaway for voters who want government to do fewer things but do core things better is straightforward. Screening guidelines are already in place, and prevention is cheaper than late-stage treatment that drives up premiums and public spending.

The remaining work is practical and local: making sure people hear the message, can book an appointment without jumping through hoops, and aren’t boxed out by insurance fine print. The numbers show the cost of delay is real.